Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin

The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration

(2014) Dimitrios Panidis et al.   Hormones-International Journal of Endocrinology and Metabolism

Is there a place for incretin therapies in obesity and prediabetes?

(2013) Jens Juul Holst et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Circulating Sfrp5 Is a Signature of Obesity-Related Metabolic Disorders and Is Regulated by Glucose and Liraglutide in Humans

(2012) Wenjing Hu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Adipokines, Insulin Resistance and Hyperandrogenemia in Obese Patients with Polycystic Ovary Syndrome: Cross-Sectional Correlations and the Effects of Weight Loss

(2012) Nikolaos Spanos et al.   Obesity Facts

Obesity and PCOS: Implications for Diagnosis and Treatment

(2012) Richard Legro   SEMINARS IN REPRODUCTIVE MEDICINE

Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome - A meta-analysis of randomised trials

(2011) Neil JOHNSON   AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY

Cellular and molecular mechanisms of metformin: an overview

(2011) Benoit Viollet et al.   CLINICAL SCIENCE

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

(2010) J. Rosenstock et al.   DIABETES CARE

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

(2010) A. Maida et al.   DIABETOLOGIA

Sfrp5 Is an Anti-Inflammatory Adipokine That Modulates Metabolic Dysfunction in Obesity

(2010) N. Ouchi et al.   SCIENCE

Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review

(2009) Stefano Palomba et al.   ENDOCRINE REVIEWS

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome

(2009) Evanthia Diamanti-Kandarakis et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Targeting insulin sensitivity in the treatment of polycystic ovary syndrome

(2009) Renato Pasquali et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides

(2009) Rania Abu-Hamdah et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Can Women Be Identified That Will Derive Considerable Cardiovascular Benefits from Postmenopausal Estrogen Therapy?

(2008) Thomas B. Clarkson   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome

(2008) Karen Elkind-Hirsch et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Drug Insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal

(2008) Andrea Dunaif   Nature clinical practice. Endocrinology & metabolism